ArticleJournal of clinical & translational endocrinology2019
A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences.
Article in Journal of clinical & translational endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Hypothyroidism is a risk factor for transient ischemic attack: A meta-analysis.Saudi medical journal · 2025Pooled it
- Concomitant Use of Levothyroxine and Proton Pump Inhibitors in Patients with Primary Hypothyroidism: a Systematic Review.Journal of general internal medicine · 2021Pooled it
- Protein carbonylation as a modulator of fibrin clot properties in thyroid disorders: impact of therapy.Journal of thrombosis and thrombolysis · 2026Article
- Developing a machine learning-based predictive model for levothyroxine dosage estimation in hypothyroid patients: a retrospective study.Frontiers in endocrinology · 2025Article
- Hypothyroidism and metabolic cardiovascular disease.Frontiers in endocrinology · 2024Review
- Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults.Reviews in endocrine & metabolic disorders · 2022Review
- Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption.Frontiers in endocrinology · 2022Review
- Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review.Endocrine connections · 2020Review
- Levothyroxine Therapy in Thyrodectomized Patients.Frontiers in endocrinology · 2020Review
- L-T4 Therapy in the Presence of Pharmacological Interferents.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCross-sectional studies have reported that TSH above or close to the upper normal limit correlates with unfavorable metabolic and cardiovascular outcomes. Certain medications impair intestinal absorption of levothyroxine (L-T4), resulting in undertreated hypothyroidism (
methodIn this retrospective study in collaboration with 8 family physicians, we enrolled adults with primary hypothyroidism under L-T4 therapy that, for 2 years minimum, was not associated with those medications (non-exposure, baseline) and that, for another 2 years minimum, it was (exposure). Outcomes were serum levels and proportions of serum TSH levels >4.12 mU/L, and proportions of complications. Complications were aggravation of pre-existing or
resultA total of 114 patients were enrolled. Duration of exposure to the interfering medication was 32.1 ± 6.9 months (median 31; range 24-55). Compared with non-exposure, the exposure period resulted in greater TSH levels (2.81 ± 3.62 [median 1.79]
conclusionDuring a median period of 31 months, there are relevant consequences for L-T4 treated adult hypothyroid patients resulting from hyperthyrotropinemia caused by medications impairing L-T4 absorption. This should be taken into account by future guidelines on hypothyroidism management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.